| Resonance Health appoints distributor for the Middle East.
Resonance Health has today announced the appointment of Gulf Drug Establishment as distributor for the FerriScan service in the United Arab Emirates, Saudi Arabia and Egypt. FerriScan is a non-invasive, MRI-based service for the measurement of liver iron overload.
“This appointment is an important step in developing a market that holds great potential for the Company” said Liza Dunne, Managing Director of Resonance Health. “There is a high number of patients with iron overload in the region caused by the regular blood transfusions they receive to treat their underlying condition. FerriScan is now recognised internationally as the gold standard in the measurement of liver iron concentration, and iron overload”. Gulf Drug Establishment is a leading player in healthcare products and services in the UAE and is one of the first companies to have started pharmacies, private clinics and healthcare marketing and distribution services in the country.
The partnership between Resonance Health and Gulf Drug Establishment will provide patients attending the Emirates Thalassaemia Society in Dubai with immediate access to FerriScan, a state-of-the-art facility primarily funded by the Dubai Health Authority. It is anticipated that the FerriScan service will be established in other Middle Eastern countries during 2012.
“FerriScan has had strong support from key clinicians in the region who have seen its beneficial effects on patient management through clinical trials” said Ms Dunne. “We are delighted that they will now be able to access the service for the routine clinical management of their patients.”
FerriScan is currently available through over 120 centres in more than 20 countries.
|
Login
